![]() ![]() Agena’s MassArray SARS-CoV-2 Panel kits and instruments are ready for immediate deployment, and we are equipped to supply millions of tests each month.”įor more information, visit Agena Bioscience. “Agena proactively sourced and secured materials to provide uninterrupted product availability to our customers. “The unique characteristics of the Agena detection technology provide significant supply chain advantages,” explains Jason Halsey, senior vice president of Technology and Operations. Agena Bioscience insights Based on 2 survey responses What people like Trust in colleagues Sense of belonging Support from manager Overall impressions Senior Territory Manager, NYC, NJ, PA (Former Employee) - San Diego, CA - AugSmall and nimble company providing a low cost solution for genotyping. With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability. “Most real time qPCR-based assays target only two or three targets on the viral genome.” “The MassArray SARS-CoV-2 Panel is the only assay on the market with 5 viral genome targets multiplexed into a single reaction, making it robust against potential mutations arising in the viral genome,” says Darryl Irwin, PhD, vice president of Scientific Affairs. The single-reaction panel targets five regions of the viral genome and provides excellent accuracy and sensitivity. This position will be be working in the Analytical Services department and will be responsible for development, optimization, and implementation of new.From Maravai LifeSciences - Mon, 21:57:20 GMT - View all San Diego, CA jobs. The MassArray System is the perfect tool for that.” Agena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY Dx PLUS assays for gene-specific mutation. Tweet Scientist - Maravai LifeSciences - San Diego, CA 1 month ago - By San Diego Biotechnology. ![]() “Agena is proud to offer a truly scalable platform to support the increasing demand for high-throughput SARS-CoV-2 testing,” says Peter Dansky, CEO of Agena Bioscience.” To address the crisis presented by covid-19, labs need to cost-effectively process large numbers of samples. Agena Bioscience, San Diego, announced that its MassArray SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus, which causes covid-19, has been granted emergency use authorization from the FDA.Ĭlinical laboratories can process thousands of samples each day for less than $10 per sample running the assay on a single MassArray instrument, making it one of the highest throughput SARS-CoV-2 tests available under the emergency use authorization program. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |